TrialInvestigational new drugs2016

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.

Elaine McWhirter et al.PubMed ↗Publisher ↗

No numbers read from the abstract.